Results 151 to 160 of about 3,654 (190)

Sofosbuvir/velpatasvir

Reactions Weekly, 2022
  +11 more sources

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

New England Journal of Medicine, 2015
BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C ...
Graham R Foster, Nezam Afdhal, Stuart K Roberts   +2 more
exaly   +2 more sources

Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment

Clinical Pharmacokinetics, 2018
The pharmacokinetics and safety of velpatasvir, a potent pangenotypic hepatitis C virus NS5A inhibitor, were evaluated in two hepatic impairment studies: a phase I study in hepatitis C virus-uninfected subjects and a phase III study (ASTRAL-4) in hepatitis C virus-infected patients.In the phase I study, subjects with moderate or severe hepatic ...
Erik Mogalian, Diana M. Brainard, Anu Osinusi, Lisa Moorehead, Bernard Murray, Kah Hiing John Ling, Robert Perry, Craig Curtis, Eric Lawitz, Kenneth Lasseter, Thomas Marbury, Anita Mathias   +11 more
openaire   +2 more sources

Sofosbuvir/velpatasvir

Reactions Weekly, 2021
  +8 more sources

Sofosbuvir/velpatasvir

Reactions Weekly, 2023
  +5 more sources

Sofosbuvir/velpatasvir

Reactions Weekly, 2019
  +6 more sources

Sofosbuvir/velpatasvir/Sofosbuvir/velpatasvir/voxilaprevir

Reactions Weekly, 2023
openaire   +1 more source